Using mRNA lipid nanoparticles to treat pre-eclampsia
mRNA lipid nanoparticles for pre-eclampsia
This study is testing a new way to treat pre-eclampsia during pregnancy by using tiny particles to deliver helpful messages to the placenta, with the goal of improving blood flow and lowering high blood pressure, so that both moms and babies can be healthier.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10946273 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for pre-eclampsia, a serious condition that can occur during pregnancy, characterized by high blood pressure and potential harm to both mother and baby. The approach involves using lipid nanoparticles to deliver mRNA directly to the placenta, aiming to improve blood flow and reduce hypertension. By targeting the delivery of therapeutic mRNA, the researchers hope to create a more effective treatment that addresses the underlying causes of pre-eclampsia rather than just managing its symptoms. This innovative method could lead to better outcomes for pregnant individuals affected by this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are pregnant individuals diagnosed with pre-eclampsia after 20 weeks of gestation.
Not a fit: Patients who are not pregnant or those who do not have a diagnosis of pre-eclampsia will not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option that alleviates pre-eclampsia symptoms and improves maternal and fetal health.
How similar studies have performed: While the use of mRNA delivery systems is a novel approach in this context, similar strategies have shown promise in other therapeutic areas, indicating potential for success.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Mitchell, Michael J — University of Pennsylvania
- Study coordinator: Mitchell, Michael J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.